• Publications
  • Influence
Malignant gliomas in adults.
Approximately 5% of patients with malignant gliomas have a family history of gliomas. Some of these familial cases are associated with rare genetic syndromes, such as neurofibromatosis types 1 and 2,Expand
  • 3,288
  • 140
  • PDF
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
PURPOSE We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial. Expand
  • 1,990
  • 100
  • PDF
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonanceExpand
  • 1,567
  • 73
  • PDF
Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma
Malignant gliomas are the most common and deadly brain tumors. Nevertheless, survival for patients with glioblastoma, the most aggressive glioma, although individually variable, has improved from anExpand
  • 1,072
  • 47
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
PURPOSE To determine the frequency, characteristics, and reversibility of peripheral neuropathy from bortezomib treatment of advanced multiple myeloma. PATIENTS AND METHODS Peripheral neuropathyExpand
  • 549
  • 28
  • PDF
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
UNLABELLED We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 andExpand
  • 313
  • 24
  • PDF
Bevacizumab for recurrent malignant gliomas
Background: Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, may have activity in recurrent malignant gliomas. At recurrence some patients appear to developExpand
  • 520
  • 21
Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors
The Quality Standards Subcommittee seeks to develop scientifically sound, clinically relevant practice parameters for the practice of neurology. Practice parameters are strategies for patientExpand
  • 699
  • 20
  • PDF
Management of brain metastases.
Brain metastases are the most common type of brain tumor in adults and are an increasingly important cause of morbidity and mortality in cancer patients. In recent years, important advances have beenExpand
  • 538
  • 19
Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases.
BACKGROUND The spread of systemic cancer to the brain is a common complication for cancer patients. Conventional radiotherapy offers modest palliation, and surgery is helpful only for the patientExpand
  • 566
  • 18